TriSalus Life Sciences, Inc. (TLSI)

TriSalus Life Sciences is a clinical-stage medical device and biopharmaceutical company focused on treating patients with advanced liver and pancreatic cancers that are difficult for conventional therapies to reach effectively. The company’s core asset is a proprietary drug-delivery technology platform called Pressure-Enabled Drug Delivery (PEDD) that modulates the pressure and flow of infusion during cancer treatment, delivering more therapeutic agent to the tumor tissue while limiting damage to healthy tissue nearby.

What is TriSalus trying to solve?

Liver cancer and pancreatic cancer are among the deadliest malignancies. For patients with hepatocellular carcinoma or advanced pancreatic tumors, treatment options are limited and outcomes remain grim. Chemotherapy and radiation work globally across the body and damage healthy cells. What oncologists and patients need is a way to concentrate the therapeutic dose at the tumor site while sparing healthy tissue. TriSalus’s approach is to engineer the infusion process itself — controlling the pressure and flow of fluid delivery so that the drug concentrates in the tumor and less of it leaks into surrounding blood vessels and organs.

The concept is straightforward in theory: modulate pressure during infusion, and you change where the drug goes. In practice, it requires precise engineering and extensive testing. TriSalus has built proprietary hardware (infusion devices) and clinical expertise around this principle.

What products has TriSalus brought to market?

The TriNav infusion system is an FDA-cleared medical device used in transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) procedures for patients with primary liver cancer or metastases to the liver. These are interventional radiology procedures in which a catheter delivers a drug or radioactive particles directly into the blood vessels feeding a tumor. The TriNav system improves the precision and control of that delivery. It is already in use in clinical centers, generating revenue from device sales and procedure support.

The second FDA-cleared device is the Pancreatic Retrograde Venous Infusion device, designed specifically for pancreatic cancer. It is currently in Phase 1 clinical trials, meaning it is still being tested in a small number of patients to establish safety and tolerability. If successful, it could open a new treatment pathway for locally advanced pancreatic cancer, one of the most treatment-resistant cancers.

Beyond devices, TriSalus is also developing nelitolimod, an investigational immunotherapy intended to stimulate the immune system to attack tumor cells. Nelitolimod is in Phase 1 trials for melanoma and several liver cancers. This is a longer-timeline asset; immunotherapies take years to develop and face high clinical failure rates. But if successful, nelitolimod would diversify TriSalus’s revenue beyond device sales into pharmaceutical revenue.

How does TriSalus make money right now?

The company generates revenue from the TriNav infusion system, which is already FDA-cleared and in clinical use. Revenue is earned through device sales and supporting services at cancer centers and hospitals performing liver-directed therapies. The company reported 2025 second-quarter revenue of approximately $11.6 million, up 57% year-over-year, a sign that hospital adoption of the TriNav system is accelerating.

This is early-stage revenue from a single approved product, so it is volatile and concentrated. The company is not yet profitable on an operating basis. TriSalus is burning cash to fund clinical trials for the pancreatic device and the nelitolimod immunotherapy. For investors, the path to profitability depends on whether the TriNav system achieves sustained adoption at hospitals nationwide and whether the pipeline programs (particularly the pancreatic device and immunotherapy) succeed in clinical trials and reach the market within the next three to five years.

What is the investment thesis?

For believers, TriSalus has several compelling elements. First, it has a cleared device already generating revenue and showing accelerating adoption — not a hypothetical technology, but a product hospitals are paying for. Second, the broader market for liver-directed cancer therapy is growing as oncologists recognize that direct targeting works better than systemic chemotherapy for some patients. Third, the pancreatic cancer indication is massive — hundreds of thousands of patients worldwide, with few good options — so if the Pancreatic Retrograde Venous Infusion device works, the addressable market is enormous. And fourth, the management team is experienced in medtech and oncology.

The risks are also substantial. The company is pre-profitability with limited cash. Clinical trials can fail, and immunotherapy trials in particular have high failure rates. Hospital adoption of the TriNav system, while accelerating, could plateau. Competitors could enter the space with alternative drug-delivery approaches. And for investors with short time horizons, waiting years for pipeline programs to mature and generate revenue is a test of patience.

How does TriSalus fit in the broader cancer-treatment landscape?

Cancer therapy has been shifting toward more targeted approaches: precision medicine, immunotherapy, and combination treatments rather than blunt systemic chemotherapy. TriSalus’s focus on local drug delivery to the tumor site fits this trend. The company is not trying to replace chemotherapy or immunotherapy, but to make existing therapies more effective by concentrating them where they are needed. That positioning — as an enabler of better drug delivery rather than a standalone therapy — makes it complementary to the broader oncology ecosystem.

The immunotherapy work (nelitolimod) reflects a bet that oncologists will increasingly want to activate immune surveillance of tumors rather than relying only on chemical or radiation damage. If that bet is correct, and if nelitolimod proves effective in clinical trials, it could become a major component of TriSalus’s long-term business. If the immunotherapy approach does not work as hoped, the company remains a medical device play focused on the TriNav system and the pancreatic device.

What should investors watch?

Track TriNav adoption by counting the number of hospitals and cancer centers using the system and the quarterly revenue growth rate. Adoption acceleration would signal that the device is gaining traction and becoming standard of care. Plateauing adoption would suggest the market is saturating or hospitals are shifting to competitors.

Monitor clinical trial progress on the Pancreatic Retrograde Venous Infusion device and nelitolimod carefully by following press releases and SEC filings. Clinical trial results can be binary events — success or failure — with large implications for valuation. Negative data on the pancreatic device or immunotherapy would be a major headwind; positive results would be transformative.

Watch the balance sheet and cash burn rate. As a pre-profitability company, TriSalus needs to maintain enough cash to fund clinical trials and operations through the next inflection points. Any significant cash raise or equity dilution would be worth understanding, as would any commentary from management on when they expect the company to reach cash flow breakeven.

Finally, monitor the regulatory environment for liver-directed cancer therapy and the reimbursement landscape. If insurance companies and government programs make decisions to reimburse TriNav-assisted procedures at attractive rates, that accelerates adoption. If reimbursement is capped or restricted, growth slows. Regulatory and reimbursement commentary in earnings calls and 10-K filings is a key signal.